Successful rapid liposomal amphotericin B desensitization in pediatric case series.

IF 2.6 3区 医学 Q2 ALLERGY Allergy and asthma proceedings Pub Date : 2024-05-01 DOI:10.2500/aap.2024.45.240008
Cankat Genis, Zeynep Sengul Emeksiz, Sule Buyuk Yaytokgil, Tayfur Ginis, Candan Islamoglu, Emine Dibek Misirlioglu
{"title":"Successful rapid liposomal amphotericin B desensitization in pediatric case series.","authors":"Cankat Genis, Zeynep Sengul Emeksiz, Sule Buyuk Yaytokgil, Tayfur Ginis, Candan Islamoglu, Emine Dibek Misirlioglu","doi":"10.2500/aap.2024.45.240008","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Liposomal amphotericin B (LAMB) is a crucial agent in the treatment of invasive fungal diseases caused by a wide variety of yeasts and molds. In the presence of an infection caused by a fungal agent resistant to alternative antifungal drugs, desensitization may be the only option to continue treatment. However, there is insufficient information and consensus with regard to amphotericin B desensitization protocols in the pediatric age group. <b>Objective:</b> We present our experience with five cases of patients in whom successful desensitization protocols were applied with LAMB, along with a review of the literature on pediatric cases. We also provide a sample desensitization protocol that we successfully applied. <b>Methods:</b> Pediatric patients who continued their treatment with the successful rapid desensitization protocol conducted at the Paediatric Allergy and Immunology Clinic of the Ministry of Health Ankara City Hospital between September 2019 and September 2023 were examined. Desensitization protocols were applied based on Castells' desensitization protocol. <b>Results:</b> Five patients ages between 5 and 12 years were referred to us due to the development of anaphylaxis during their treatment with LAMB. Anaphylaxis is diagnosed clinically, according to the European Academy of Allergy and Clinical Immunology guidelines: anaphylaxis (2021 update). A 16-step desensitization protocol was prepared by using LAMB solutions at four different dilutions (0.001, 0.01, 0.1, and 1 mg/mL). Each solution consisted of four steps, with a 15-minute infusion for each step. The patients were premedicated with 1 mg/kg/dose methylprednisolone and an antihistamine. <b>Conclusion:</b> The data we present on the successful application of a sample protocol to five cases, particularly in a pediatric setting, are noteworthy valuable contributions to the field, which demonstrates the feasibility and success of rapid desensitization with LAMB in pediatric patients. This can provide important insights and potentially serve as a reference for medical professionals working with similar cases in the future.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 3","pages":"201-206"},"PeriodicalIF":2.6000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11399775/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy and asthma proceedings","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2500/aap.2024.45.240008","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Liposomal amphotericin B (LAMB) is a crucial agent in the treatment of invasive fungal diseases caused by a wide variety of yeasts and molds. In the presence of an infection caused by a fungal agent resistant to alternative antifungal drugs, desensitization may be the only option to continue treatment. However, there is insufficient information and consensus with regard to amphotericin B desensitization protocols in the pediatric age group. Objective: We present our experience with five cases of patients in whom successful desensitization protocols were applied with LAMB, along with a review of the literature on pediatric cases. We also provide a sample desensitization protocol that we successfully applied. Methods: Pediatric patients who continued their treatment with the successful rapid desensitization protocol conducted at the Paediatric Allergy and Immunology Clinic of the Ministry of Health Ankara City Hospital between September 2019 and September 2023 were examined. Desensitization protocols were applied based on Castells' desensitization protocol. Results: Five patients ages between 5 and 12 years were referred to us due to the development of anaphylaxis during their treatment with LAMB. Anaphylaxis is diagnosed clinically, according to the European Academy of Allergy and Clinical Immunology guidelines: anaphylaxis (2021 update). A 16-step desensitization protocol was prepared by using LAMB solutions at four different dilutions (0.001, 0.01, 0.1, and 1 mg/mL). Each solution consisted of four steps, with a 15-minute infusion for each step. The patients were premedicated with 1 mg/kg/dose methylprednisolone and an antihistamine. Conclusion: The data we present on the successful application of a sample protocol to five cases, particularly in a pediatric setting, are noteworthy valuable contributions to the field, which demonstrates the feasibility and success of rapid desensitization with LAMB in pediatric patients. This can provide important insights and potentially serve as a reference for medical professionals working with similar cases in the future.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在儿科病例系列中成功实现快速脂质体两性霉素 B 脱敏。
背景:脂质体两性霉素 B(LAMB)是治疗由多种酵母菌和霉菌引起的侵袭性真菌疾病的重要药物。在真菌病原体对其他抗真菌药物产生耐药性的情况下,脱敏可能是继续治疗的唯一选择。然而,关于儿科两栖霉素 B 脱敏治疗方案的信息和共识尚不充分。目的:我们介绍了五例成功使用 LAMB 脱敏方案的患者的经验,并回顾了有关儿科病例的文献。我们还提供了成功应用的脱敏方案样本。方法对 2019 年 9 月至 2023 年 9 月期间在卫生部安卡拉市医院儿科过敏与免疫诊所成功实施快速脱敏方案并继续接受治疗的儿科患者进行了研究。脱敏方案以卡斯特尔斯的脱敏方案为基础。结果:五名年龄在 5 至 12 岁之间的患者因在使用 LAMB 治疗过程中出现过敏性休克而转诊至我院。过敏性休克是根据《欧洲过敏与临床免疫学学会指南:过敏性休克》(2021 年更新版)进行临床诊断的。通过使用四种不同稀释度(0.001、0.01、0.1 和 1 毫克/毫升)的 LAMB 溶液,制备了 16 步脱敏方案。每种溶液包括四个步骤,每个步骤的输注时间为 15 分钟。患者使用 1 毫克/千克/剂量的甲基强的松龙和抗组胺药进行预处理。结论我们所提供的关于在五个病例中成功应用样本方案的数据,尤其是在儿科环境中的应用,是该领域值得注意的宝贵贡献,证明了在儿科患者中使用 LAMB 快速脱敏的可行性和成功性。这可以为今后处理类似病例的医疗专业人员提供重要的启示和潜在的参考。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.70
自引率
35.70%
发文量
106
审稿时长
6-12 weeks
期刊介绍: Allergy & Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists. The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma. Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
期刊最新文献
Real-world surveillance of standardized quality (SQ) house dust mite sublingual immunotherapy tablets for 3 years in Japan. A case of a rash after tetanus-diphtheria-pertussis and meningococcal vaccination. Eating increases disease activity in pediatric patients with symptomatic dermographism. A systematic review and meta-analysis exploring the bidirectional association between asthma and gastroesophageal reflux disease in children. Abstracts presented at the Eastern Allergy Conference May 30-June 2, 2024, Palm Beach, Florida.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1